Grant ID DP220039
Awarded On August 17, 2022
Title Single Dose 186RNL for Leptomeningeal Metastases: Multicenter Phase 1/2a Study to Determine MTD/MFD, Safety & Efficacy, Leading to Pivotal Registrational Trial
Program Product Development Research
Award Mechanism Texas Company Product Development Awards
Institution/Organization PLUS Therapeutics, Inc.
Principal Investigator/Program Director Andrew Sims
Cancer Sites Breast, Lung and Bronchus, Skin
Contracted Amount $17,613,605*

*Pending contract negotiation

Lay Summary

PLUS Therapeutics' Rhenium-186 NanoLiposome (186RNL) is a novel radiotherapeutic being developed to combat rare and difficult-to-treat cancers. Currently in clinical development for recurrent glioblastoma, 186RNL is safe and well-tolerated while delivering a radiation dose to the tumor that is up to 15 times higher than typically achievable with standard radiation therapy. PLUS now plans to develop 186RNL to treat leptomeningeal metastases (LM), a rare but typically fatal complication of advanced cancer affecting the fluid-lined structures surrounding the brain and spinal cord. LM affects over 110,000 people in the U.S. every year and, even with the best available care, is rapidly fatal with...

Read More